These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 21227751)

  • 1. Immunotherapy for persistent viral infections and associated disease.
    van der Burg SH; Arens R; Melief CJ
    Trends Immunol; 2011 Mar; 32(3):97-103. PubMed ID: 21227751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Annual disease burden due to human papillomavirus 16 and 18 infections in Finland.
    Syrjänen KJ
    Scand J Infect Dis Suppl; 2009; 108():2-32. PubMed ID: 19939209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Annual disease burden due to human papillomavirus (HPV) 6 and 11 infections in Finland.
    Syrjänen KJ
    Scand J Infect Dis Suppl; 2009; 107():3-32. PubMed ID: 19408160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virus-associated immunopathology: animal models and implications for human disease. 1. Effects of viruses on the immune system, immune-complex diseases, and antibody-mediated immunologic injury.
    Allison AC; Beveridge WI; Cockburn WC; East J; Goodman HC; Koprowski H; Lambert PH; van Lochem JJ; Miescher PA; Mimms CA; Notkins AL; Torrigiani G
    Bull World Health Organ; 1972; 47(2):257-64. PubMed ID: 4404992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human papillomavirus-specific immune therapy: failure and hope.
    Nieto K; Gissmann L; Schädlich L
    Antivir Ther; 2010; 15(7):951-7. PubMed ID: 21041909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune modulation by helminthic infections: worms and viral infections.
    Kamal SM; El Sayed Khalifa K
    Parasite Immunol; 2006 Oct; 28(10):483-96. PubMed ID: 16965284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Animal models for development of therapeutic HPV16 vaccines (review).
    Bubeník J
    Int J Oncol; 2002 Jan; 20(1):207-12. PubMed ID: 11743666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic vaccination in chronic hepatitis B virus carriers.
    Pol S; Michel ML
    Expert Rev Vaccines; 2006 Oct; 5(5):707-16. PubMed ID: 17181443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic human papillomavirus vaccination.
    Albers AE; Kaufmann AM
    Public Health Genomics; 2009; 12(5-6):331-42. PubMed ID: 19684445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human papillomavirus vaccines.
    Breitburd F; Coursaget P
    Semin Cancer Biol; 1999 Dec; 9(6):431-44. PubMed ID: 10712890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA-based immunotherapy: potential for treatment of chronic viral hepatitis?
    Beckebaum S; Cicinnati VR; Gerken G
    Rev Med Virol; 2002; 12(5):297-319. PubMed ID: 12211043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [How the bovine viral diarrhea virus outwits the immune system].
    Peterhans E; Jungi TW; Schweizer M
    Dtsch Tierarztl Wochenschr; 2006 Apr; 113(4):124-9. PubMed ID: 16716045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CoVal fusions: a therapeutic vaccine platform using heat shock proteins to treat chronic viral infection and cancer.
    Neefe JR; Chu NR; Mizzen L
    Dev Biol (Basel); 2004; 116():193-200; discussion 229-36. PubMed ID: 15603193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Toward cervical cancer prevention: strategies employed in the development of HPV vaccines].
    de la Cruz-Hernández E; Contreras-Paredes A; Lizano-Soberón M
    Rev Invest Clin; 2006; 58(6):586-97. PubMed ID: 17432291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TA-CIN, a vaccine incorporating a recombinant HPV fusion protein (HPV16 L2E6E7) for the potential treatment of HPV16-associated genital diseases.
    Hibbitts S
    Curr Opin Mol Ther; 2010 Oct; 12(5):598-606. PubMed ID: 20886392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccines against human papillomavirus and cervical cancer: promises and challenges.
    Mahdavi A; Monk BJ
    Oncologist; 2005 Aug; 10(7):528-38. PubMed ID: 16079320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C; Sanda MG
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.